Abstract
Introduction:
Anti-amyloid antibodies have the potential to become the standard of care in Alzheimer’s Disease (AD) and large datasets from clinical trials allow the testing of predictive models on fluid biomarkers and functional outcomes. However, identifying an easily accessible biomarker to determine the time to switch to maintenance therapy, and identifying patient profiles with optimal cognitive benefit, are still unresolved issues in clinical practice.
Methods:
Predicted changes in monomers, oligomers, protofibrils and plaques were simulated using a well-validated Quantitative Systems Pharmacology model based on biophysical and biological assumptions of amyloid synthesis, aggregation and clearance. This model was combined with a previously calibrated computational neuronal network model of cognitive outcome in AD patients by introducing the effect of amyloid and tau oligomers on specific voltage- and ligand-gated ion channels, informed by preclinical studies.
Results:
The model accounted for 70% and 50% of the variance of clinically observed changes in plasma p-tau181 and Clinical Dementia Rating-Sum Of Boxes (CDR-SOB) respectively, in clinical trials of seven amyloid antibodies. We derived an antibody specific normalized decrease of plasma p-tau181 (−15% for donanemab, −45% for aducanumab and −75% for lecanemab) to determine trial duration for achieving central amyloid negativity. Using the concept of information processing bandwidth, the model suggests that anti-amyloid antibodies slow the cognitive worsening compared to placebo while at the same time lowering plasma p-tau181 levels by reducing neuronal firing. Finally, the model suggests that independently from the degree of amyloid reduction, the beneficial cognitive effect of treatment decreases with more advanced neuronal pathology and higher baseline tau-load. This provides a hypothesis for the impact of disease pathology and gender effect on functional outcomes with lecanemab and gantenerumab.
Discussion:
With further validation, this model has the capability to support optimization of clinical trial design for amyloid-tau combination therapy.
1 Background
With the approval of amyloid modulating biologics, focus has turned to optimizing access in clinical practice–however, current uptake is limited due to the expensive tests for measuring amyloid dynamics in patients during treatment. The gold-standard remains PET imaging of central amyloid load (defined as the total mass of soluble and insoluble Abeta species in the Interstitial Fluid), but a simpler and more accessible method to determine the time at which patients reach amyloid negativity and can be switched to maintenance therapy could help greatly in the uptake of these new therapeutics. While an earlier study suggested antibody-specific changes in CSF amyloid-beta 42 (Aβ42) can be used (), a more accessible biomarker, such as plasma biomarkers that can report on dynamics of amyloid load during and after treatment, would be very helpful. In this regard, longitudinal observational studies have shown that changes in various forms of plasma p-tau181 can inform about the central amyloid load (), and secondary readouts from Phase 3 studies with amyloid antibodies have documented a range of plasma p-tau181 or CSF p-tau181 changes at different time points after start of the treatment (). However, a systematic study for their use in determining timing of central amyloid negativity is lacking.
More importantly, while changes in amyloid load as measured by standardized uptake value ratio (SUVr) grossly correlate with cognitive improvements over placebo, the contribution of changes in intermediate, but inaccessible, amyloid-beta (Abeta) species in driving cognitive outcome is unclear. This becomes important as a number of therapeutic antibodies with preferential activity against oligomers and more modest impact on SUVr are currently in clinical development with the rationale that they can result in a functional clinical benefit.
A previous publication used a semi-empirical approach to link amyloid, tau and cognitive functioning (). To address these two objectives more quantitatively, here we used a QSP model of amyloid aggregation that is well-validated using group average data on the clinical effect of six antibodies () and has recently been shown to generalize for other antibodies and other clinical scenarios (). This model allows simulation of the effect of different antibodies with their appropriate dosing schedules on the dynamics of Abeta monomers, oligomers and protofibrils. Modeling the dynamics of these Abeta soluble oligomers is extremely interesting as new technological advances have demonstrated in a longitudinal study that Abeta oligomers peak early, well before tau pathology ().
Using regression analysis, we can then identify the contribution of these inaccessible Abeta species to experimentally observed changes in p-tau181 and cognition in actual clinical trials and compare to the correlation with observed changes in a readily accessible biomarker such as amyloid SUVr.
The purpose of this report is to provide a quantitative and biologically plausible mechanistic relationship between changes in various central amyloid species and reduction in p-tau181 fluid biomarkers and cognitive performance on the other hand.
In particular, we explore whether the plasma p-tau181 biomarker could be used to indicate the time at which amyloid load drops below the threshold for positivity and how this biomarker changes during the maintenance stage after treatment halt. Using a virtual patient trial, we will investigate the robustness of this plasma biomarker for monitoring central amyloid load for a large number of different individual patient baselines and characteristics.
Levels of secreted tau molecules, as reflected in plasma or CSF p-tau181 are driven by changes in neuronal firing (). As amyloid pathology in late mild cognitive impairment (MCI) and early prodromal AD is associated with hyperactivity (; ) due to its effects on glutamate, nAChR and K+ conductance (; ; ; ; ), it makes sense that reducing amyloid burden would lower tau secretion and therefore observed levels in plasma and CSF p-tau181. This provides a qualitative mechanistic rationale for the link between amyloid and tau changes.
To derive a more quantitative relationship between amyloid changes and plasma p-tau181 changes for clinical practice, we use an actual computational neuroscience model (; ; ; ) that captures the effect of amyloid pathology on neuronal firing. Next, we generate a quantitative relationship between neuronal firing and tau secretion, based on preclinical experimental data (). Most importantly, this will allow us to derive a quantitative relationship between changes in various Abeta species, impact on neuronal firing and tau secretion and ultimately fluid p-tau181 biomarkers for a large number of individual patient baselines and characteristics in order to determine the timing at which the central amyloid load reaches negativity.
Post-hoc analyses of anti-amyloid antibodies have highlighted the impact of baseline tau pathology, not on amyloid biomarkers but most importantly on the functional clinical outcomes (). Also, a recent study suggests that lecanemab as compared to gantenerumab and aducanumab has a higher affinity for small diffusible Abeta species () that are prominent in early disease, possibly leading to a more robust functional outcome. We address these questions using a computational neuroscience model that has been calibrated with ADAS-Cog scores () after implementing the documented effects of these Abeta and tau oligomers on voltage- and ligand gated ion channels. This would allow us to explore the effect of amyloid therapy on neuronal firing in appropriate networks driving functional cognitive outcome.
Finally, such a combined mechanistic Amyloid-Tau QSP model linking biomarker and functional outcomes could inform future clinical trial design of combination therapies ().
2 Methods
2.1 Amyloid aggregation model
Calculation of intermediate Aβ42 species such as ISF monomer, oligomer (dimer to 16-mer), protofibril (17–23-mer) and plaques (24-mer and above) is performed using the amyloid aggregation QSP model (). Basically, this model simulates (1) the synthesis of Aβ40 and Aβ42, (2) the breakdown of monomers through IDE and neprilysin, (3) the forward aggregation of monomers into higher-order aggregates, (4) the backward generation of monomers from higher-order aggregates, (5) microglia-dependent amyloid clearance, and (6) the distribution of soluble monomers from the brain into the CSF and plasma. Drug exposure of amyloid antibodies is modeled using a minimal PBPK model () and the binding of Immunoglobulin G1 (IgG1) isotypes to the Fc gamma receptor (FcγR) on microglia triggers a phenotypic switch in microglia resulting in higher clearance of amyloid species. Extensive documentation on equations and parameters can be found in the Supplementary Material (; ) The model is well calibrated using both natural history data and the pharmacodynamic effect of six antibodies on amyloid biomarkers and has recently been applied to explore practical challenges in clinical practice (). The model runs in QSPDesigner () and ODE solver is based on backward differentiation formula (BDF) with an absolute tolerance of 10E-15. A typical run on a laptop CPU takes about 20 min to simulate 16,000 time points.
2.2 Clinical data on p-tau181 biomarker
To collect the clinical data on changes in plasma p-tau181 or CSF p-tau181 biomarkers and on cognitive changes (CDR-SOB), we used Certara’s CODEX database (Certara CODEx and Clinical Outcomes Databases|Quantifying data) from donanemab, lecanemab, aducanumab, gantenerumab, solanezumab, crenezumab and bapineuzumab clinical trials. We identified 35 datapoints of p-tau181 changes and 36 datapoints for cognitive changes versus placebo at different time points, different doses and titration schedules.
Careful analysis of the reported changes with donanemab, lecanemab and aducanumab suggests that lecanemab has the greatest effect on reduction of plasma or CSF p-tau181. It is of interest to more closely examine the effect of lecanameb. In the CLARITY Phase 3 trial (), a decrease of 18 pg/mL for CSF p-tau181 and a plasma decrease of 0.6 pg/mL was reported. Given that baseline CSF p-tau181 is around 30 pg/mL in Braak stage I and II, rising to 50 pg/mL in Braak stage III and above (), the change in CSF p-tau181 is well above 50%. On the other hand, a 0.6 pg/mL reduction (only a 10% reduction from baseline) in plasma p-tau181 as reported in VanDyck’s Supplementary Figure SH is well below detection limit (technical fiche Quanterix Simoa, suggesting that the y-axis label in this figure (p-tau changes after lecanemab treatment) might be more correctly interpreted as the normalized decrease in plasma p-tau181. Such a decrease is more in line with the reported 12.3 pg/mL decrease for CSF p-tau181 in the adaptive Phase 2 trial (). For donanemab’s TRAILBLAZER trial, a −0.12 log10 value corresponding to a 10^-0.12 or 0.75 was mentioned, corresponding to a 25% decrease in CSF p-tau 217 (). All values are provided in Supplementary Table S1.
2.3 Multivariate regression for plasma p-tau181 changes and cognitive outcome
We simulated the changes in intermediate Abeta in our amyloid aggregation model, such as ISF Aβ42 monomers, Aβ42 oligomers, Aβ42 protofibrils and Aβ42 plaques normalized to baseline values for the different clinical trial designs.
Statistical analysis of linear and multivariate regression between the simulated changes in Abeta species and the observed outcomes on plasma p-tau181 and CDR SOB is executed using the Statistical Analysis Package of Excel software.
2.4 Time to reach amyloid negativity
For relating the fluid p-tau181 levels to the treatment duration for achieving central amyloid negativity, we simulated clinical trials of aducanumab, lecanemab, and donanemab at different starting baseline amyloid levels. Using the formula from the multivariate analysis, we calculated the corresponding plasma p-tau181 levels from the trajectory of the four different Abeta species. We determined the duration to reach a central amyloid load of 25 CL and calculated a value for plasma p-tau181 at the time of amyloid negativity for each of the antibodies and as a function of amyloid baseline for each virtual patient in the simulated trial.
2.5 Virtual patient trial
We generated a virtual patient population (n = 1,000), with about 75% APOE4+ subjects first for the longitudinal unmedicated condition to determine the natural trajectory of amyloid aggregation by sampling parameters associated with biological processes from a Gaussian distribution with a CV of 10%–30% depending upon the individual parameter (). This reflects grossly the distribution of amyloid biomarkers observed in the Phase 3 studies.
Biological processes unique for individual patients include synthesis and degradation of Aβ monomers, forward and backward rate constants of primary nucleation for higher-order aggregates, enhanced forward aggregation due to secondary nucleation, breakdown of protofibrils into smaller aggregates and uptake of various Abeta species by microglia cells. Additionally, variability of drug uptake at the Blood-Brain Barrier and the phenotypic switch from low to high phagocytosing phenotype after binding of the antibody to the Fc-gamma receptor (FcγR) on microglia cells can be observed.
We identified the age at which the SUVr amyloid exceeded 1.30 or 47 centiloids (Age*). We subsequently simulated an 18-month trial for donanemab, lecanemab and aducanumab for the same patient where the start of the trial was delayed according to the following relationship, assuming an average delay of 6 years between diagnosis and treatment start.
Where RND (random) is sampled from a uniform distribution between 0 and 1. The average age of patients at the start of treatment was 74.4 ± 4.49 years (range 61–90 years), while the average baseline amyloid load was 120 ± 20 CL (range 98–180). Gender was implemented using an average body weight of 55 kg for females and 79 kg for males and was evenly distributed (50/50).
Readouts of interest include dynamics of free monomeric Aβ42, oligomeric Aβ42, protofibril Aβ42, plaque Aβ42 and the clinical outcomes of CSF Aβ42, SUVr. This allows us to compare the effect of the three drugs on exactly the same patient population.
2.6 Mechanistic model of amyloid and tau effects on cognitive readouts
Based on the premise that cognitive outcome is driven by properties of neuronal firing in well-defined neuronal circuits, we simulated realistic firing patterns using a biophysical representation of the opening and closing of relevant voltage- and ligand-gated ion channels ().
This computational neuroscience model, calibrated to longitudinal and interventional clinical data on cognitive outcome, such as ADAS-Cog has been published before (). Basically, the computer model generates biophysically realistic action potential dynamics in a cortical microcolumn with 80 pyramidal cells and 40 GABA inhibitory neurons, leading to an appropriate balance of excitation and inhibition. At a specific time, a short 50 msec stimulus gives rise to a continuous firing of a subset of pyramidal neurons over a number of seconds. This time span is reminiscent of a working memory trace stability and is strongly correlated to an actual N-back working memory task (). Although the interventional studies used for calibration mostly used short-term symptomatic treatment affecting neuronal firing, the model also takes into account a progressive neuronal and synapse loss, mostly due to increasing tau pathology based on long-term longitudinal studies.
Aβ40 and Aβ42 monomers have a differential impact on glutamate and alpha 7 nicotinic acetylcholine receptor (α7 nAChR) neurotransmission, whereby the long peptide Aβ42 has a monotonic inhibitory effect on glutamate tone, while Aβ40 shows an inverse U-shape dose-response (). The model, based on these assumptions, was able to explain three clinical datasets on pharmacological challenges in Abeta positive and Abeta negative MCI patients (; ) and predicted the transient functional worsening of beta-amyloid precursor protein cleaving enzyme 1 or BACE-inhibitors.
We further implemented the effect of soluble Abeta oligomer species on neuronal firing based on the following effects of oligomeric Abeta reported in preclinical experiments: (1) decrease in potassium conductance, gK (), (2) increase in α7 nAChRconductance (), (3) increase in pyramidal excitatory AMPA receptor (), (4) increases in GABAergic conductance on inhibitory neurons likely due to decreases in interneuron gK () and the voltage gated potassium Kv3 channel in parvalbumin cortical interneurons (). These combined interventions lead to a higher firing frequency with increasing levels of Abeta species (; ; ).
Soluble tau oligomers have been documented to increase the width of the action potential (; ) and affect the speed of action potential propagation (). This effect was driven by a direct interaction of tau oligomers with voltage-gated potassium K+ and sodium Na+ channels. To fully explain the observed quantitative effects on action potential propagation as observed in multielectrode array (MEA) studies of human induced pluripotent stem cells (hIPSCs) from frontal temporal dementia (FTD) donors (), the effect of tau oligomers was implemented using a maximal 10% reduction of Na channel conductance, and a maximal reduction of 10% for voltage-gated K+ channels in the whole neuron. This was then extrapolated to our Alzheimer’s Disease QSP model based on the assumption that the V337M FTD mutation had the same impact on voltage-gated ion channels.
We implemented the effects of Abeta soluble oligomers as follows. Calculating levels of soluble Abeta oligomers from the observed SUVR changes (between 1 and 2), we arrive atwhere superscripts int and pyr refer to inhibitory and pyramidal cells, respectively and superscripts e-I and e-e refer to excitatory-inhibitory and excitatory-excitatory projects respectively. The subscripts “base” refers to the baseline value of the conductance (i.e., in the absence of any amyloid and tau pathology).
The effects of tau pathology on the K+ and Na+ channels are implemented as follows with Tau PET SUVRtau between 1 and 3
gNa = gNa base *(1-(SUVRtau−1)/20) with Na-channels only considered in the Axonal Initial Segment (AIS).
These values were chosen to align best with the clinical changes
The values of the above defined coupling constants between amyloid and tau SUVR and the impact of various neuronal processes is determined from observations on plasma p-tau changes as outlined in Methods Section 7.
This computational neuroscience QSP model runs in the open-source NEURON software () and uses a time-resolution of 0.5 msec. Calculation of the relevant readouts (see below) is done over 30 episodes of 12 s each (24,000 time points). A single run takes about 20 min laptop CPU time; hyperthreading allowd to run 12–16 simulations in parallel.
An interesting readout for cognitive performance of the QSP model is the information bandwidth based on the Shannon entropy (). This is based on the observation that not the firing frequency, but the inter-spike interval variability, is associated with better cognitive performance as it can be encoded with a larger number of bits in a binary word. Here we project the action potential of all pyramidal cells and interneurons on one time axis and determine the Shannon entropy of the inter-spike interval distribution. The detailed implementation is described in the Supplementary Material (Supplementary Section S3). Both high and low frequency firing have a more limited variability and therefore can carry less information. This approach captures the reduced information capacity of a hyperactive state, as observed in high-amyloid load MCI patients.
Disease state was implemented using a state-dependent elimination of neurons and synapses. We define four prodromal (MCI-like) states, MCI1 to MCI4 with increasing fractional loss of synapses (1%–4%) and neurons (1%–4%) in our computational neuroscience network. This is accompanied by a compensatory increase in N. Basalis Choline acetyl transferase (ChAT) activity boosting acetylcholine (ACh) levels (). At AD0, the onset of Alzheimer symptoms, from previous calibration (), the fraction of neurons and synapses lost is 5%, increasing to 6.9% and 5.29% at AD6 and 8.1% and 5.48% at AD12, respectively. Note that an additional synapse loss is implemented after the neuron loss, adding to the synapses that are lost because of neuron elimination. Due to the increased N Basalis pathology in Alzheimer’s Disease, the compensatory upregulation of Ach synthesis as observed in the MCI case is lost, we therefore assume a 30% decrease in Ach levels for the AD0, AD6 and AD12 states ().
2.7 Relationship between neuronal firing and tau secretion
Presynaptic release of tau proteins into the synaptic cleft has been suggested to be mediated by the synaptic vesicle release machinery (), and therefore can be dependent upon the neuronal firing activity of the afferent neuron. As amyloid antibodies decrease neuronal firing, this leads to decreased secretion of tau and p-tau181 which can be detected in CSF and plasma as a decrease in tau biomarker levels.
To determine the quantitative relationship between firing and tau release, we started from preclinical data in wild-type and D280K transgenic mouse with a variety of pharmacological interventions (picrotoxin, NMDA, the mGLUR2 modulator LY341495 and TTX) to modulate the in vivo cortical firing frequency (). We simulated the same pharmacological interventions in the NEURON computational neuroscience cortical model and derived a relationship between the firing frequency and the corresponding experimentally determined tau increase.
Using the average decrease of plasma p-tau181 from the lecanemab trials, we can derive the corresponding decrease in neuronal firing, which would then define the coupling factor between oligomer concentration and effect on neuronal firing as described in Methods Section 6.
2.8 Relationship between ADAS-Cog and CDR-SOB
As most of the anti-amyloid therapies used CDR-SOB as primary outcome, we wanted to derive a relationship with ADAS-Cog so that we could use the previously calibrated ADAS-Cog model (). We used Certara’s CODEX database and identified 298 cases where both ADAS-Cog and CDR-SOB were reported.
This ultimately results in the formula CDR-SOB = 3.5–0.02*(InfCon-415). The derivation of the information content, InfCon, was based on the statistics of inter-spike intervals and is explained in Supplementary Section S8.
3 Results
3.1 Regression analysis of QSP model outcomes with clinical observation of p-tau181 changes
For the 35 clinical data-points on plasma p-tau181 changes with amyloid antibody treatment, we simulated the trajectories of intermediate inaccessible biomarker dynamics of Abeta species (monomers, oligomers, protofibrils and plaques) using the appropriate clinical trial design for each of the studies.
Figure 1 shows that correlation between simulated changes and observed changes in p-tau181 is the highest for changes in protofibril Aβ42 (r2 = 0.62), oligomeric Aβ42 (r2 = 0.56), followed by ISF monomeric Aβ42 (r2 = 0.39) and finally plaque Aβ42 (r2 = 0.05). This suggests that changes in p-tau181 are driven by more soluble Abeta species in the aggregation cascade. The correlation between experimental changes in plasma p-tau181 and predicted changes in SUVr in the QSP model can account for only 25% of variability.
FIGURE 1
A multivariate regression analysis using these simulated model outcomes can account for 69% of the variability of p-tau181 changes (p-value = 0.00029). Using this information, we can derive the equation below with the appropriate contributions of each Abeta species. The following formula captured almost as good the change in plasma p-tau181 biomarker explaining 66% of the variability.where AbX*(t) = AbX(t)/AbX (0) with X = mono, oligo, proto, plaque.
And corresponding values C1 (0.812), C2 (0.53), C3 (−1.93), C4 (0.23), C5 (30), C6 (0.43), C7 (1.45) and C8 (−0.04).
3.2 Simulating dynamics of p-tau181 biomarker in virtual patient trial
When applying this formula to the simulated individual Abeta species outcomes, we can calculate the decrease in p-tau181 at the time that the SUVr reaches negativity (a value of 25 CL) for each of the 1,000 virtual patients treated with the different antibodies.
Figure 2 shows the simulated plasma p-tau181 changes for each of the virtual patients at the time of reaching amyloid negativity for that patient baseline amyloid load. The outcomes suggest a small decrease (10%–20% effect size) in p-tau181 for donanemab. In contrast, both aducanumab (41%) and lecanemab treatment (77%) lead to a substantial change in p-tau. This suggests that there is not “one size fits all” for the use of a plasma p-tau threshold for determining the time of amyloid negativity but that it is dependent upon the pharmacology of the antibody. Similar results have been obtained for a virtual patient population consisting of nonAPOE4 subjects. The most convenient way for the patients to have plasma samples for p-tau181 taken is at the infusion times (i.e., Q4W or Q2W). Careful analysis of the time at which amyloid negativity is reached (see Supplementary Material Section S2) suggests that it is worthwhile to start analyzing these samples from six and 12 months onwards for lecanemab and aducanumab respectively.
FIGURE 2
3.3 Mechanistic model for amyloid-tau relationship
3.3.1 Relating cortical firing to tau secretion
While the previous results were derived from empirical associations between amyloid modeling outcomes and clinical findings, in this section we will explore a more mechanistic understanding of the changes in plasma p-tau181. Tau secretion has been documented to be driven by synaptic activity (); to this end we simulated preclinical experiments, to the extent that average extracellular tau level in vivo ranges from 0.7 to about 1 nM in wild-type mice with 1%–2% of seed-competent tau and 4%–6% of tau in exosomes ().
In the Yamada experiment, wild-type mice were treated with seven pharmacological interventions (see Supplementary Material Section S5) that increased ISF tau levels in a range between 0% and 200%. We ran these same pharmacological interventions in 3 different QSP models (corresponding to a heathy case, a “MCI” type case with minimal loss of synapses and neurons and compensatory increase of Ach and an “AD” case with more pronounced loss of synapses and neurons in addition to a hypo-cholinergic state, see also Methods Section 6) to identify the changes in firing rates and correlated these with the observed increase in ISF tau. A weighted slope between fractional increase in ISF tau and firing was determined to be 12.92 (i.e., for each percent increase in neuronal firing, a 12.9% increase in ISF tau was predicted). For the clinically observed decreases in plasma p-tau181 (see Methods Section 2), this would correspond to a range between 4% (aducanumab) and 6% change (lecanemab) in firing frequency.
3.3.2 Modeling the effect of soluble Abeta species changes on functional outcomes
In general, post hoc analyses from the clinical trials with anti-amyloid antibodies suggest that the functional cognitive worsening was smaller for earlier stages of pathology and lower baseline tau levels (; ).
Given that our analysis of functional readout on CDR-SOB in the clinical trials was dependent upon changes in all Abeta species (Figure 3), we next investigated whether implementation of the documented biological effects of soluble Abeta species (defined as monomers, oligomers and protofibrils) on neuronal activity could reproduce the observed effects on functional outcomes.
FIGURE 3
First, in the absence of any tau pathology, after implementing specific effects of soluble Abeta42 species (Methods Section 6), the model predicts increased firing with a higher level of soluble Abeta42 species as expected (Supplementary Figures S2–S5 in Supplementary Material Section S4; Supplementary Figure S5). The firing frequency increases proportionally with the level of soluble Abeta42 species with baseline levels depending upon the disease state (lower firing frequency with more advanced AD pathology), while the information processing capacity has a more complex relationship.
We derive a quantitative relationship between changes in the different affected processes (NMDA, AMPA, α7 nAChR and gK) and soluble Abeta species from the clinical observations on the reduction in neuronal firing corresponding to the observed clinical decrease in plasma p-tau181. We define amyloid oligomer strength as the relation between absolute amyloid oligomer levels and effects on electrophysiological properties. As demonstrated in Supplementary Material Section S5, the reduction in neuronal firing can be achieved for donanemab by a decrease of amyloid oligomer strength of 2% (for an early AD subject) to 8% (for an early MCI subject). Conversely, for lecanemab, this can be achieved by a 4% decrease in the level of soluble Abeta42 species (mild AD subject) to a 10% decrease (early MCI subject) (see Supplementary Table S3).
3.3.3 Modeling the effect of soluble Abeta species changes in different tau environments on CDR-SOB predictions
Once we quantified the impact of soluble Abeta species on neuronal firing, we then added the effect of tau pathology on voltage gated ion channels (Methods Section 8). However, unlike the amyloid case, we do not have the same information for quantifying the effect of pathological tau changes on neuronal firing.
At any specific level of tau pathology, increasing soluble Abeta species increases firing in a disease state dependent way, as outlined above for the no tau case. We arbitrarily divided tau oligomer levels in 8 units from Tau0 – no detectable tau level as in the healthy control case–to Tau8 – associated with Braak stage VI. Because increasing tau pathology by itself reduces firing frequency due to its effect on Na-conductances, the relative increase triggered by the same increase in Abeta oligomer strength is greater for higher tau pathologies. For example, the increase in firing frequency for Tau0 versus Tau8 level is 5.2% vs. 6.4% for the MCI1 state, 3% vs. 11% for the MCI4 state and 22.1% vs. 26.6% for the AD12 state, respectively.
Similarly, at any level of baseline tau pathology, the predicted CDR-SOB features an inverse U-shape dose-response for the level of soluble Abeta42 species as observed in the no tau case. As expected, increasing tau pathology in general decreases cognitive performance as measured by the information content (see Supplementary Figure S7). In addition, increasing disease state shifts the peak of best cognitive performance (highest information capacity) towards higher Abeta oligomer values. When averaging over all tau pathology levels, the best cognitive performance at MCI1 is at an Abeta oligomer strength of zero, at 5.5% for MCI3, at 10% for AD0, and finally 12.5% for AD12. The level of soluble Abeta42 species at which optimal cognitive performance happens is relatively independent of tau level (see Supplementary Figure S7).
The QSP model was previously calibrated using 28 datapoints from ADAS-Cog readouts in clinical trials for symptomatic therapies (). We used the CODEX database of more than 100 Alzheimer disease trials for identifying clinical datapoints for both CDR-SOB and ADAS-Cog to derive a relationship between these two functional scales (Supplementary Material Section S8; Supplementary Figure S8) that would convert information content readout from the QSP model to actual CDR-SOB values.
3.3.4 Simulating CDR-SOB changes with amyloid antibodies
Once we had simulated CDR-SOB as a function of amyloid, tau oligomers, and disease state, we then simulated the trajectories of patients in the placebo and active treatment arms in anti-amyloid clinical trials under varying scenarios. The model predicts that increased soluble Abeta42 species in the placebo arm increases the average firing frequency. The clinical observations that placebo patients worsened around 1.6 points on the CDR-SOB over the span of 18 months () as a consequence of oligomer and plaque amyloid increase provide a calibration for the simulated firing increase. Figure 4 illustrates the effects of reducing soluble Abeta42 species with lecanemab vs. the placebo arm in a simulation of the 18-month trials, suggesting the simulated firing frequency and cognitive performance moving in opposing direction for the two treatment arms. The figure also graphically depicts the concept of information content, suggesting that reducing soluble Aβ42 oligomers by lecanemab reduces the firing frequency, resulting in larger information bandwidth (number of words or information to be carried by that spike train).
FIGURE 4
We next investigated the trajectory of different individual cases as a function of possible changes in disease state (i.e., increasing number of synapses and neurons lost) and progression of tau pathology (Figure 5).
FIGURE 5
As we do not have any information about the progression of the disease or tau load from the clinical trials, we simulated a variety of scenarios. When the patients remain in the same disease state and do not increase their tau load (Figure 5C), the average CDR-SOB difference between treatment and placebo is −0.46, −0.33, and 0.87 for the low disease/low baseline tau, intermediate disease state/moderate baseline tau, and advanced disease state/high baseline tau level respectively (negative values indicating better performance). Other analyses showing the same trend are reported in Supplementary Material Section S7.
Figure 5 shows the difference between treated patients and placebo for other baseline scenarios where pathology is increased by one unit (Figure 5A), where tau load is increased by 1 unit (Figure 5D) and where both pathology and tau load are increased by 1 unit (Figure 5B) over the time-course of the 18-month clinical trial. Blue colors are associated with less progression of CDR-SOB compared to placebo and red colors identify baseline conditions where placebo functional trajectory outperforms treated patients. The figures demonstrate that the blue colors tend to dominate the left lower part of the plotted surfaces, suggesting that the greatest beneficial effects of reducing soluble oligomers with amyloid therapies are in subjects with low pathology (MCI1-MCI3) and relatively low tau load (Tau0-Tau2).
4 Discussion
This paper reports on the development and applications of a combined amyloid-tau-functional outcome mechanistic QSP model, informed by the biology of amyloid and tau and their effects on voltage- and ligand-gated ion channels, leading to changes in neuronal firing dynamics. We use the concept of virtual patients to extend the clinical observations from the group level data to inform about outcomes in a more real-world clinical practice environment.
The model suggests that changes in plasma p-tau181 could be used to inform the duration of anti-amyloid treatment to reach central amyloid negativity at the individual patient level. Outcomes suggest that, at the time for reaching amyloid negativity, donanemab, aducanumab and lecanemab do change plasma p-tau181 to about 15%–20%, 40%–50%, and 70%–80% respectively. The decrease predicted for donanemab might be at the limit of detectability. Here we focused on p-tau181 based on the majority of clinical data for this epitope. In principle, other p-tau epitopes could be used after appropriate calibration.
This outcome is driven by the observation that tau secretion is neuronal activity dependent. While this has been demonstrated directly in in vitro cell cultures (; ; ) and animal models using pharmacological interventions () and optogenetics (), there is also evidence from MAPT gene mutation V337M Tau hIPSC that tau interacts with proteins of synaptic vesicle recycling and fusion and could use synaptic vesicle release (). Indirect evidence in aged humans includes the observations from the Harvard Ageing Brain Study that tau deposits using the radiotracer AV-1451 are associated with the projection regions of hot spots in BOLDfMRI, for example, hippocampal BOLDfMRI related to inferior temporal tau deposition (; ).
This would also suggest that tau levels might also be affected by the various comedications and common genotype variants that affect neuronal firing, ranging from reductions (benzodiazepines) to increases (cholinergic standard-of-care). It also suggests that changes in this fluid tau biomarker are a direct and acute effect of amyloid therapy on neuronal firing and not necessarily indicate an effect on tau pathology progression.
The reduction of the uptake of misfolded tau protein in the afferent neuron by anti-amyloid therapies could over time lead to less formation of soluble intracellular tau oligomers and therefore reduction of tau pathology, although timelines are likely much longer than the typical duration of an amyloid antibody treatment. This also opens the intriguing possibility that drugs aimed at soluble Abeta oligomers, such as lecanemab, over time might have a greater impact on tau pathology, as they have a greater cumulative effect on neuronal firing and tau reduction due to the longer time to achieve amyloid negativity.
The difference in plasma p-tau dynamics can be explained by the differential pharmacology of the amyloid antibodies. In our amyloid QSP model, we do not discriminate between regular Abeta and N3pE in forming plaques. Donanemab targets the N3pE epitope of Abeta, and reduces SUVR very fast by predominantly removing insoluble plaques that are at the very end of the aggregation cascade. In contrast, because lecanemab and aducanumab to a lesser degree, have a greater effect on reducing intermediate soluble oligomers and protofibrils, they affect neuronal firing more, leading to a more pronounced reduction of tau secretion. This also extends to a new generation of anti-amyloid antibodies currently in clinical trials that are highly specific for soluble oligomers.
When implementing amyloid and tau oligomer effects on ligand- and voltage-gated ion channels, the model predicts a better functional cognitive outcome of amyloid antibody therapy in conditions with a lower pathology and a lower tau burden, especially for an early disease state. This is in line with post hoc observations of the clinical effect of lecanemab () and to a lesser extent donanemab ().
The basis for this hypothesis stemmed from imaging studies suggesting that in this prodromal AD state, amyloid deposits correspond to metabolic hotspots and hyperactivity to the point that these subjects have a greater probability of suffering from subclinical seizures (). Both amyloid and tau pathology play a role () in epileptogenesis. For example, in brain tissue from refractory epileptic patients, increased amyloid and tau pathology has been found (). In fact, hyperactivity neuropsychiatry symptoms such as disinhibition, irritation and agitation are common in late MCI and early AD () and are associated with brain morphology in specific brain regions and with regional hyperperfusion (; ; ; ).
The model generates the following hypothesis for this observation. Through their effect on glutamate, α7 nAChR and K+ channels, increased soluble amyloid oligomer levels, in early AD and MCI, trigger disinhibition-mediated hyperactivity in the brain. Cognitive tests have suggested that this hyperactivity leads to deficits in specific cognitive domains, which could be alleviated with the anti-seizure medication levetiracetam (). Other studies however did not find a large degree of hyperactivity (; ) either due to regional variability or detection limit, suggesting that this increased neuronal firing can be limited. This is in line with our modeling outcomes suggesting that a 5% change in average firing frequency can already lead to substantial changes in ISF, CSF and plasma free tau.
Neuronal firing hyperactivity results in an initial decrease in cognitive capacity, as measured by information capacity in our simulations. This information capacity is proportional to the variability in inter-spike interval. Higher neuronal firing frequency, driven in majority by the refractory period of neuronal firing restricts the range of inter-spike intervals. Studies in human subjects suggest that cognitive performance is not always proportional to neuronal firing but is better associated with statistics of inter-spike interval, as for instance quantified by the concept of information content (; ; ; ). A recent study suggests variability in BOLDfMRI signal, not absolute intensity, is a potential new biomarker of functional neurological disorders (). Therefore, reducing neuronal firing frequency can enhance the information bandwidth of the neuronal system and improve cognitive performance as illustrated in Figure 4.
The QSP model suggests that the effect of the soluble oligomers decrease on voltage- and ligand-gated ion channels by different anti-amyloid antibodies leads to a decrease in neuronal firing, counteracting the hyperactivity in these MCI and early AD patients.
The Shannon entropy concept intervals is an efficient way to quantify information based on the variability of inter-spike interval (; ). By lowering the firing frequency, the anti-amyloid antibodies drive the system from a high firing frequency–where the inter-spike interval is closer to the refractory period–to a lower regimen with a broader distribution of inter-spike intervals. At the same time, this decreases the secretion of tau proteins, likely both in the monomeric and misfolded form.
The model also provides a hypothesis for the observed lack of cognitive benefits in conditions with increased pathology at baseline (i.e., patients more progressed in the disease). This is likely because firing frequency tends to decrease with increasing pathology because of (1) loss of compensatory upregulation of ChAT enzyme that increases cholinergic tone and (2) loss of synapses and neurons as the disease progresses. As a consequence, the beneficial effect of lowering neuronal firing is reduced.
An interesting corollary is the suggestion that this approach could be used to directly simulate the functional effect of therapeutic interventions that block the binding of Abeta oligomers to membrane proteins, such as CT1812 ().
A similar argument holds when considering tau pathology. The effect of tau oligomers on the strategically positioned Na+channels in the Axon Initial Segment, in addition to K+ channels dominate any small effect of Abeta oligomers on neuronal activity. This is in line with preclinical observations (; ) and with the fact that cognitive performance in AD patients is related more strongly with tau pathology than with amyloid pathology ().
Clinical imaging data suggest that the relation between tau and atrophy is mediated by Abeta positivity in lateral superior temporal and insula and the cognitive function (CDR-SOB) driven by tau-atrophy relationship is mediated by Abeta positivity in rostromedial and paracentral brain region while on average, the tau burden is significantly higher in Abeta positive brain regions (). Of interest to note is the reduced functional benefit of lecanemab in female subjects () in clinical trials. Our analysis suggests that subjects with a higher tau baseline are functionally less responsive to lecanemab therapy, despite a similar reduction in amyloid load. Given that female patients have more tau pathology compared to male patients at the same age () our model could provide a mechanistic interpretation of this gender effect.
The approach in this paper is complementary to a previous model () that is based on a semi-empirical model linking amyloid and tau changes to cognitive outcome based on a large number of clinical data. Here we attempt to bring in a mechanistic understanding of the amyloid and tau pathology effects on neuronal firing in a realistic neuronal network that we believe is driving human cognition. This allows us to take into account the pharmacodynamic effects of comedications and common genotypes, such as COMTVal156Met and 5-HTTrs23351 () on the amyloid and tau mediated cognitive outcomes to explain the large variability in functional outcome in clinical trials despite similar effects on amyloid and tau biomarkers.
There are several limitations in this model. First, the aggregation of amyloid species from monomers into plaques in the Interstitial Fluid is very complex and not accessible to intermediate experimental readouts. While certainly not incorporating all the ongoing processes, our model takes into account multiple aspects of the aggregation cascade, including forward and backward reactions and is the most comprehensive of all published amyloid aggregation QSP models (). It has also predicted a new titration schedule for donanemab that optimizes the amyloid clearance/ARIA side-effects ().
Second, the model does not differentiate between different forms of phosphergeorylated tau, as it assumes that all forms of tau are secreted through the same pathway. Recent studies indicate that plasma ptau217 might be a more sensitive biomarker for amyloid pathology (). We assume that unlike total tau, these post-translationally modified tau proteins are derived solely from the brain. While the absolute levels in plasma might differ, the relative normalized decrease from baseline in individual patients is expected to be independent of the tau phosphorylation site. While the QSP model has been calibrated on reported-tau181 changes with the different antibodies, it should be acknowledged that the baseline plasma levels of phosphorylated tau, can be different depending upon the epitope.
Thirdly, the QSP model assumes that human cognition can be simulated by spike train distribution of activity in a cortical microcolumn. While we have previously demonstrated that this is a close proxy for working memory performance–as assessed with a N-back working memory test–in an Alzheimer’s, healthy and schizophrenia environment (; ), it has not been validated for other aspects of human cognition, such as episodic memory or social functional performance and cognition.
The effect of amyloid and tau oligomers on electrophysiology properties of neuronal circuits is derived from preclinical experiments using rodent or hIPSC based models; with the extrapolation to the human pathology situation not yet demonstrated. Another major issue is the lack of a strong quantitative relationship between levels of Abeta oligomers and their downstream effect on voltage- and ligand-gated ion channels. Many preclinical experiments use unreasonably high concentrations to elicit any detectable effects. Here, by combining the impact of Abeta oligomer dynamics from the QSP model in the lecanemab case with the clinically observed change in plasma p-tau181 using the previously derived relationship between neuronal firing and tau secretion, we can derive a clinically realistic anchor point on the Abeta oligomer strength, i.e., the relation between absolute amyloid oligomer levels and effects on electrophysiological properties.
In contrast, the effects of amyloid plaques on neuron electrophysiological properties are much less studied. One hypothesis starts from the observation that microglia are attracted to plaques in vivo, forming a barrier to capture soluble oligomers leaking out of the plaque () and in that process secreting pro-inflammatory cytokines. These cytokines have been documented to affect neuronal function, for instance IL10 enhancing VTA DA action (), while CXCL12 increases excitability in rat amygdala (). TNFalpha increases excitability (), reduces GABA transmission in R47H TREM2 rats (; ) and is increased in the pre-plaque stage (; ). Other mechanisms include the association of TGFB1 with GABAergic dysfunction in patients (; )and small-conductance, calcium activated potassium Channel subtype 2 (SK2) channel upregulated after cytokine exposure (). These processes can be introduced in the QSP model to provide a better prediction of the effect on CDR-SOB of the antibodies that predominantly affect plaques, such as donanemab.
The simulations presented here do not take into account the impact of various comedications (cholinergic medications, antidepressants, benzodiazepines and antipsychotics) on amyloid and tau biomarker and clinical outcome. While there is little evidence that comedications affect the dynamics of amyloid biomarkers after anti-amyloid treatment, they can certainly affect tau secretion through their effect on neuronal firing and certainly clinical outcome (). Expanding this approach to simulate virtual twins of real patients that differ with age, gender, amyloid and tau baseline pathology and comedications is beyond the scope of this paper, but will be the subject of a follow-up report.
A major limitation is the absence of a clear link between the tau pathology as measured by PET imaging and the effect of the soluble tau oligomers on Na+ and K+ channel function. A possible strategy is to explicitly model the aggregation dynamics from tau monomers to oligomers and ultimately to neurofibrillary tangles to derive levels of soluble tau oligomers from Tau-PET imaging studies. Unlike the amyloid aggregation cascade, these processes take place in the neuronal cytoplasm with additional axonal transport and active clearance mechanisms through the autophagy-lysosomal and ubiquitin pathways.
However, the fact that we can semi-qualitatively retrieve the clinical observation of a differential response for anti-amyloid antibodies as a function of baseline disease state and tau load suggests that the QSP model captures a substantial part of the pharmacodynamic effect on functional outcome. Future work will attempt to quantitatively predict changes in CDR-SOB with amyloid or tau therapies when more clinical data becomes available.
The QSP model was previously calibrated with ADAS-Cog clinical data, while the anti-amyloid antibody trials used CDR-SOB as the primary outcome. While reporting on somewhat different clinical symptoms, we have found a tight correlation between close to 300 parallel readouts of these two clinical scales in various patient subgroups. This provides some confidence that the QSP model can also predict CDR-SOB as a clinical readout.
In summary, this report proposes a mechanistic QSP model to better understand the relationship between amyloid and tau dynamics on biomarkers and functional outcomes. Continuously testing its predictions against the clinical data on amyloid therapies in clinical practice might help to identify responders to amyloid and tau therapies on cognitive scales and support identifying optimal trial designs for combination therapy.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.
Ethics statement
Ethical approval was not required for the study involving humans in accordance with the local legislation and institutional requirements. Written informed consent to participate in this study was not required from the participants or the participants’ legal guardians/next of kin in accordance with the national legislation and the institutional requirements.
Author contributions
HG: Conceptualization, Methodology, Software, Writing – original draft, Writing – review and editing. SS: Data curation, Formal Analysis, Investigation, Writing – review and editing. AG: Data curation, Formal Analysis, Investigation, Writing – review and editing. PvdG: Project administration, Supervision, Writing – review and editing.
Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Acknowledgments
We are extremely grateful to our former colleagues Silke Bergeler and Mike Walker, who helped develop the amyloid QSP model.
Conflict of interest
The authors were employed by company Certara Predictive Technologies, Applied Biosimulation.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2026.1813290/full#supplementary-material
References
1
AltunaM.Olmedo-SauraG.Carmona-IraguiM.ForteaJ. (2022). Mechanisms involved in epileptogenesis in alzheimer’s disease and their therapeutic implications. Int. J. Mol. Sci., 23, 4307. 10.3390/ijms23084307
2
AndrewsD.DucharmeS.ChertkowH.SormaniM. P.CollinsD. L.et alAlzheimer’s Disease Neuroim (2025). The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect. Alzheimer’s Dementia J. Alzheimer’s Assoc.21 (1), e14467. 10.1002/alz.14467
3
BakkerA.KraussG. L.AlbertM. S.SpeckC. L.JonesL. R.StarkC. E.et al (2012). Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron74 (3), 467–474. 10.1016/j.neuron.2012.03.023
4
BatemanR. J.SmithJ.DonohueM. C.DelmarP.AbbasR.SallowayS.et al (2023). Two phase 3 trials of gantenerumab in early Alzheimer’s disease. N. Engl. J. Med.389 (20), 1862–1876. 10.1056/NEJMoa2304430
5
BilletteO. V.ZieglerG.AruciM.SchützeH.KizilirmakJ. M.RichterA.et al (2022). Novelty-Related fMRI responses of precuneus and medial temporal regions in individuals at risk for Alzheimer disease. Neurology99 (8), e775–e788. 10.1212/WNL.0000000000200667
6
BilousovaT.MillerC. A.PoonW. W.VintersH. V.CorradaM.KawasC.et al (2016). Synaptic amyloid-beta oligomers precede p-tau and differentiate high pathology control cases. Am. J. Pathol.186 (1), 185–198.
7
BlömekeL.RehnF.Kraemer‐SchulienV.KutzscheJ.PilsM.BujnickiT.et al (2023). Aß oligomers peak in early clinical stages of Alzheimer´s disease and proceed Tau pathology. Alzheimer’s Dementia19 (S24), e082907. 10.1002/alz.082907
8
BloomingdaleP.BakshiS.MaassC.van MaanenE.Pichardo-AlmarzaC.YadavD. B.et al (2021). Minimal brain PBPK model to support the preclinical and clinical development of antibody therapeutics for CNS diseases. J. Pharmacokinet. Pharmacodynamics48 (6), 861–871. 10.1007/s10928-021-09776-7
9
BoxerA. L.SperlingR. (2023). Accelerating Alzheimer’s therapeutic development: the past and future of clinical trials. Cell186 (22), 4757–4772. 10.1016/j.cell.2023.09.023
10
BuscheM. A. (2019). Tau suppresses neuronal activity in vivo, even before tangles form. Brain142 (Number 4), 843–846. 10.1093/brain/awz060
11
BuscheM. A.WegmannS.DujardinS.ComminsC.SchiantarelliJ.KlicksteinN.et al (2019). Tau impairs neural circuits, dominating amyloid-β effects, in Alzheimer models in vivo. Nat. Neurosci.22 (1), 57–64. 10.1038/s41593-018-0289-8
12
CavanaghC.Colby-MilleyJ.FarsoM.KranticS.QuirionR. (2011). Early molecular and synaptic dysfunctions in the prodromal stages of Alzheimer’s disease: focus on TNF-α and IL-1I. Future Neurol.6 (Number 6), 757–769. 10.2217/fnl.11.50
13
CecchettiG.AgostaF.RugarliG.SpinelliE. G.GhirelliA.ZavarellaM.et al (2024). Diagnostic accuracy of automated Lumipulse plasma pTau-217 in Alzheimer’s disease: a real-world study. J. Neurology271 (10), 6739–6749. 10.1007/s00415-024-12631-7
14
ChenZ.ChenK.LiY.GengD.LiX.LiangX.et al (2024). Structural, static, and dynamic functional MRI predictors for conversion from mild cognitive impairment to Alzheimer’s disease: Inter-cohort validation of Shanghai Memory Study and ADNI. Hum. Brain Mapp.45 (1), e26529. 10.1002/hbm.26529
15
ChristopherH, V. D.RandallB.SharonC.RobM.MarwanS.et al (2023). Lecanemab clarity AD: results from a randomised, double-blind phase 3 early Alzheimer’s disease trial. 10.1136/jnnp-2023-abn.139
16
Corriveau-LecavalierN.RajahM. N.MellahS.BellevilleS. (2021). Latent patterns of task-related functional connectivity in relation to regions of hyperactivation in individuals at risk of Alzheimer’s disease. NeuroImage Clin.30, 102643. 10.1016/j.nicl.2021.102643
17
CroftC. L.WadeM. A.KurbatskayaK.MastrandreasP.HughesM. M.PhillipsE. C.et al (2017). Membrane association and release of wild-type and pathological tau from organotypic brain slice cultures. Cell Death Dis.8 (3), e2671.
18
CrupiV.NelsonJ. D.MederB.CevolaniG.TentoriK. (2018). Generalized information theory meets human cognition: introducing a unified framework to model uncertainty and information search. Cognitive Sci.42 (5), 1410–1456. 10.1111/cogs.12613
19
DarkH. E.PatersonC.DayaG. N.PengZ.DugganM. R.BilgelM.et al (2024). Proteomic indicators of health predict Alzheimer’s disease biomarker levels and dementia risk. Ann. Neurology95 (2), 260–273. 10.1002/ana.26817
20
DiasR. D.ZenatiM. A.StevensR.GabanyJ. M.YuleS. J. (2019). Physiological synchronization and entropy as measures of team cognitive load. J. Biomed. Inf.96, 103250. 10.1016/j.jbi.2019.103250
21
DinetV.Arouche-DelapercheL.DégardinJ.NaudM. C.PicaudS.KranticS. (2022). Concomitant retinal alterations in neuronal activity and TNFα pathway are detectable during the pre-symptomatic stage in a mouse model of Alzheimer’s disease. Cells11 (10), 1650. 10.3390/cells11101650
22
DoraiswamyP. M.SperlingR. A.JohnsonK.ReimanE. M.WongT. Z.SabbaghM. N.et al (2014). Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study. Mol. Psychiatry19 (9), 1044–1051. 10.1038/mp.2014.9
23
El HaffafL. M.RonatL.CannizzaroA.HanganuA., Alzheimer’s Disease, and Neuroimaging Initiative (2024). Associations between hyperactive neuropsychiatric symptoms and brain morphology in mild cognitive impairment and Alzheimer’s disease. J. Alzheimer’s Dis.97 (2), 841–853. 10.3233/JAD-220857
24
Fernandez-PerezE. J.MuñozB.BascuñanD. A.PetersC.Riffo-LepeN. O.EspinozaM. P.et al (2021). Synaptic dysregulation and hyperexcitability induced by intracellular amyloid beta oligomers. Aging Cell20 (9), e13455. 10.1111/acel.13455
25
FerreiraR.Bastos-LeiteA. J. (2024). Arterial spin labelling magnetic resonance imaging and perfusion patterns in neurocognitive and other mental disorders: a systematic review. Neuroradiology66, 1065–1081. 10.1007/s00234-024-03323-0
26
FertanE.LamJ. Y. L.AlbertiniG.DewildeM.WuY.AkingbadeO. E. S.et al (2025). Lecanemab preferentially binds to smaller aggregates present at early Alzheimer’s disease. J. Alzheimer’s Assoc.21 (4), e70086. 10.1002/alz.70086
27
FrankaM.EdthoferA.KörnerA.WidmannS.FenzlT.SchneiderG.et al (2023). An in-depth analysis of parameter settings and probability distributions of specific ordinal patterns in the Shannon permutation entropy during different states of consciousness in humans. J. Clin. Monit. Comput.38, 385–397. 10.1007/s10877-023-01051-z
28
GeertsH.SpirosA. (2020a). Learning from amyloid trials in Alzheimer’s disease. A virtual patient analysis using a quantitative systems pharmacology approach. Alzheimer’s Dementia16 (6), 862–872. 10.1002/alz.12082
29
GeertsH.SpirosA. (2020b). Simulating the effects of common comedications and genotypes on alzheimer’s cognitive trajectory using a quantitative systems pharmacology approach. J. Alzheimer’s Dis.78 (1), 413–424. 10.3233/JAD-200688
30
GeertsH.RobertsP.SpirosA. (2013). A quantitative system pharmacology computer model for cognitive deficits in schizophrenia. CPT Pharmacometrics Syst. Pharmacol.2 (4), e36. 10.1038/psp.2013.12
31
GeertsH.SpirosA.RobertsP. (2018). Impact of amyloid-beta changes on cognitive outcomes in Alzheimer’s disease: analysis of clinical trials using a quantitative systems pharmacology model. Alzheimer’s Res. Ther.10 (1), 14. 10.1186/s13195-018-0343-5
32
GeertsH.BergelerS.WalkerM.RoseR.Van der GraafP. (2023a). Exploring treatment guidelines for amyloid therapies in Alzheimer’s Disease using predictive quantitative system pharmacology modeling. Alzheimer’s Dementia19 (S24), e082487. 10.1002/alz.082487
33
GeertsH.WalkerM.RoseR.BergelerS.van der GraafP. H.SchuckE.et al (2023b). A combined physiologically-based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer’s disease. CPT Pharmacometrics Syst. Pharmacol.12 (4), 444–461. 10.1002/psp4.12912
34
GeorgeA. A.VieiraJ. M.Xavier-JacksonC.GeeM. T.CirritoJ. R.Bimonte-NelsonH. A.et al (2021). Implications of oligomeric amyloid-beta (oAβ42) signaling through α7β2-nicotinic acetylcholine receptors (nAChRs) on basal forebrain cholinergic neuronal intrinsic excitability and cognitive decline. J. Neurosci.41 (3), 555–575. 10.1523/JNEUROSCI.0876-20.2020
35
GourmaudS.ShouH.IrwinD. J.SansaloneK.JacobsL. M.LucasT. H.et al (2020). Alzheimer-like amyloid and tau alterations associated with cognitive deficit in temporal lobe epilepsy. Brain143 (1), 191–209. 10.1093/brain/awz381
36
GuoA.LauC. G. (2022). TNF-alpha orchestrates experience-dependent plasticity of excitatory and inhibitory synapses in the anterior piriform cortex. Front Neurosci.16, 824454.
37
HanseeuwB. J.BetenskyR. A.JacobsH. I. L.SchultzA. P.SepulcreJ.BeckerJ. A.et al (2019). Association of amyloid and Tau with cognition in preclinical alzheimer disease: a longitudinal Study. JAMA Neurol.76 (8). 10.1001/jamaneurol.2019.1424
38
HerriottL.ColesM.FournierN.GaffneyE.WaggJ. (2026). Quantitative systems pharmacology models of anti-amyloid treatments for Alzheimer’s disease: a systematic review. CPT Pharmacometrics Syst. Pharmacol.15 (3), e70223. 10.1002/psp4.70223
39
HillE.KarikariT. K.MoffatK. G.RichardsonM. J. E.WallM. J. (2019). Introduction of Tau oligomers into cortical neurons alters action potential dynamics and disrupts synaptic transmission and plasticity. ENeuro6 (5). 10.1523/ENEURO.0166-19.2019
40
HillE.KarikariT. K.Lantero-RodriguezJ.ZetterbergH.BlennowK.RichardsonM. J.et al (2021). Truncating tau reveals different pathophysiological actions of oligomers in single neurons. Commun. Biol.4 (1), 1265. 10.1038/s42003-021-02791-x
41
HinesM. L.CarnevaleN. T. (2001). NEURON: a tool for neuroscientists. Neurosci. A Rev. J. Bringing Neurobiol. Neurology Psychiatry7 (2), 123–135. 10.1177/107385840100700207
42
HodgkinA. L.HuxleyA. F. (1952). A quantitative description of membrane current and its application to conduction and excitation in nerve. J. Physiology117 (4), 500–544. 10.1113/jphysiol.1952.sp004764
43
HuijbersX. W.SchultzA. P.PappK. V.LapointM. R.HanseeuwX.ChhatwalX. J. P.et al (2019). Tau accumulation in clinically normal older adults is associated with hippocampal hyperactivity. J. Neurosci.39 (3), 548–556. 10.1523/JNEUROSCI.1397-18.2018
44
IkonomovicM. D.AbrahamsonE. E.IsanskiB. A.WuuJ.MufsonE. J.DeKoskyS. T. (2007). Superior frontal cortex cholinergic axon density in mild cognitive impairment and early Alzheimer disease. Archives Neurology64 (9), 1312–1317. 10.1001/archneur.64.9.1312
45
KhedrE. M.AhmedO. G.SayedH. M.Abo-ElfetohN.AliA. M.GomaaA. M. (2020a). Electrophysiological differences in cortical excitability in different forms of dementia: a transcranial magnetic stimulation and laboratory biomarkers study. Neurophysiol. Clin.50 (3), 185–193. 10.1016/j.neucli.2020.05.001
46
KhedrE. M.GomaaA. M. S.AhmedO. G.SayedH. M. M.GameaA. (2020b). Cognitive impairment, P300, and transforming growth factor β1 in different forms of dementia. J. Alzheimer’s Dis.78 (2), 837–845. 10.3233/JAD-200885
47
KrebsC.BrillE.MinkovaL.FederspielA.Kellner-WeldonF.WyssP.et al (2023). Investigating compensatory brain activity in older adults with subjective cognitive decline. J. Alzheimer’s Dis.93 (1), 107–124. 10.3233/JAD-221001
48
KuriharaM.MatsubaraT.MorimotoS.ArakawaA.OhseK.KanemaruK.et al (2024). Neuropathological changes associated with aberrant cerebrospinal fluid p-tau181 and Aβ42 in Alzheimer’s disease and other neurodegenerative diseases. Acta Neuropathol. Commun.12 (1), 48.
49
LimY. Y.MaruffP.SchindlerR.OttB. R.SallowayS.YooD. C.et al (2015). Disruption of cholinergic neurotransmission exacerbates Aβ-related cognitive impairment in preclinical Alzheimer’s disease. Neurobiol. Aging36 (10), 2709–2715. 10.1016/j.neurobiolaging.2015.07.009
50
MatthewsR. J.HollinsheadD.MorrisonD.van der GraafP. H.KierzekA. M. (2023). QSP designer: quantitative systems pharmacology modeling with modular biological process map notation and multiple language code generation. CPT Pharmacometrics Syst. Pharmacol.12 (7), 889–903. 10.1002/psp4.12972
51
MazerN. A.HofmannC.LottD.GieschkeR.KleinG.BoessF.et al (2023). Development of a quantitative semi-mechanistic model of Alzheimer’s disease based on the amyloid/tau/neurodegeneration framework (the Q-ATN model). J. Alzheimer’s Assoc.19 (6), 2287–2297. 10.1002/alz.12877
52
McDadeE.CummingsJ. L.DhaddaS.SwansonC. J.ReydermanL.KanekiyoM.et al (2022). Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimer’s Res. Ther.14 (1), 191. 10.1186/s13195-022-01124-2
53
MinkevicieneR.RheimsS.DobszayM. B.ZilberterM.HartikainenJ.FülöpL.et al (2009). Amyloid β-induced neuronal hyperexcitability triggers progressive epilepsy. J. Neurosci.29 (11), 3453–3462. 10.1523/JNEUROSCI.5215-08.2009
54
MurthyS. R. K.SherrinT.JansenC.NijholtI.RoblesM.DolgaA. M.et al (2015). Small-conductance Ca2+-activated potassium type 2 channels regulate the formation of contextual fear memory. PLoS One10 (5), e0127264. 10.1371/journal.pone.0127264
55
OlahV. J.GoettemoellerA. M.RayaproluS.DammerE. B.SeyfriedN. T.RangarajuS.et al (2022). Biophysical Kv3 channel alterations dampen excitability of cortical PV interneurons and contribute to network hyperexcitability in early Alzheimer’s. ELife11, e75316. 10.7554/eLife.75316
56
OssenkoppeleR.SmithR.OhlssonT.StrandbergO.MattssonN.InselP. S.et al (2019). Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. Neurology92 (6), e601–e612. 10.1212/WNL.0000000000006875
57
OssenkoppeleR.CoomansE. M.ApostolovaL. G.BakerS. L.BarthelH.BeachT. G.et al (2025). Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex. Nat. Neurosci.28 (8), 1610–1621. 10.1038/s41593-025-02000-6
58
PingY.HahmE. T.WaroG.SongQ.Vo-BaD. A.LicursiA.et al (2015). Linking Aβ42-Induced hyperexcitability to neurodegeneration, learning and motor deficits, and a shorter lifespan in an Alzheimer’s model. PLoS Genet.11 (3), e1005025. 10.1371/journal.pgen.1005025
59
PontecorvoM. J.LuM.BurnhamS. C.SchadeA. E.DageJ. L.ShcherbininS.et al (2022). Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol.79 (12), 1250–1259. 10.1001/jamaneurol.2022.3392
60
PoolerA. M.PolydoroM.WegmannS.NichollsS. B.Spires-JonesT. L.HymanB. T. (2013). Propagation of tau pathology in Alzheimer’s disease: identification of novel therapeutic targets. Alzheimers Res. Ther.5 (5), 49.
61
RajdlK.LanskyP.KostalL. (2017). Entropy factor for randomness quantification in neuronal data. Neural Netw.95, 57–65. 10.1016/j.neunet.2017.07.016
62
RenS. Q.YaoW.YanJ. Z.JinC.YinJ. J.YuanJ.et al (2018). Amyloid β causes excitation/inhibition imbalance through dopamine receptor 1-dependent disruption of fast-spiking GABAergic input in anterior cingulate cortex. Sci. Rep.8 (1), 302. 10.1038/s41598-017-18729-5
63
RenS.YaoW.TambiniM. D.YinT.NorrisK. A.D’adamioL. (2020). Microglia TREM2R47H Alzheimer-linked variant enhances excitatory transmission and reduces LTP via increased TNF-α levels. ELife9. 10.7554/eLife.57513
64
RenS.BreuillaudL.YaoW.YinT.NorrisK. A.ZehntnerS. P.et al (2021). TNF-α-mediated reduction in inhibitory neurotransmission precedes sporadic Alzheimer’s disease pathology in young Trem2R47H rats. J. Biol. Chem.296. 10.1074/jbc.RA120.016395
65
RishtonG. M.LookG. C.NiZ.-J.ZhangJ.WangY.HuangY.et al (2021). Discovery of investigational drug CT1812, an antagonist of the Sigma-2 receptor complex for alzheimer’s disease. ACS Med. Chem. Lett.12 (9), 1389–1395. 10.1021/acsmedchemlett.1c00048
66
RobertsP. D.SpirosA.GeertsH. (2012). Simulations of symptomatic treatments for Alzheimer’s disease: computational analysis of pathology and mechanisms of drug action. Alzheimer’s Res. Ther.4 (6), 50. 10.1186/alzrt153
67
RobinsonB.BhamidiS.DayanE., Alzheimer’s Disease Neuroimaging Initiative (2024). The spatial distribution of coupling between tau and neurodegeneration in amyloid-β positive mild cognitive impairment. Neurobiol. Aging136, 70–77. 10.1016/j.neurobiolaging.2024.01.014
68
RonströmJ. W.WilliamsS. B.PayneA.ObrayD. J.HafenC.BurrisM.et al (2023). Interleukin-10 enhances activity of ventral tegmental area dopamine neurons resulting in increased dopamine release. Brain, Behav. Immun.113, 145–155. 10.1016/j.bbi.2023.07.007
69
SamudraN.RanasingheK.KirschH.RankinK.MillerB. (2023). Etiology and clinical significance of network hyperexcitability in Alzheimer’s disease: unanswered questions and next steps. J. Alzheimer’s Dis.92 (Number 1), 13–27. 10.3233/JAD-220983
70
SchneiderA.WeberS.WyssA.LoukasS.AybekS. (2024). BOLD signal variability as potential new biomarker of functional neurological disorders. NeuroImage. Clin.43, 103625. 10.1016/j.nicl.2024.103625
71
ShewW. L.YangH.YuS.RoyR.PlenzD. (2011). Information capacity and transmission are maximized in balanced cortical networks with neuronal avalanches. J. Neurosci.31 (1), 55–63. 10.1523/JNEUROSCI.4637-10.2011
72
SimsJ. R.ZimmerJ. A.EvansC. D.LuM.ArdayfioP.SparksJ. D.et al (2023). Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA330 (6), 512–527. 10.1001/jama.2023.13239
73
SohnP. D.HuangC. T. L.YanR.FanL.TracyT. E.CamargoC. M.et al (2019). Pathogenic tau impairs axon initial segment plasticity and excitability homeostasis. Neuron104 (3), 458–470. 10.1016/j.neuron.2019.08.008
74
SouzaB. C.PavãoR.BelchiorH.TortA. B. L. (2018). On information metrics for spatial coding. Neuroscience375, 62–73. 10.1016/j.neuroscience.2018.01.066
75
SowaJ. E.TokarskiK.HessG. (2024). Activation of the CXCR4 receptor by chemokine CXCL12 increases the excitability of neurons in the rat Central Amygdala. J. Neuroimmune Pharmacol.19 (1), 9. 10.1007/s11481-024-10112-2
76
StrongS. P.KoberleR.De Ruyter Van SteveninckR. R.BialekW. (1998). Entropy and information in neural spike trains. Phys. Rev. Lett.80 (1), 197–200. 10.1103/PhysRevLett.80.197
77
SwansonC. J.ZhangY.DhaddaS.WangJ.KaplowJ.LaiR. Y. K.et al (2021). A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimer’s Res. Ther.13 (1), 80. 10.1186/s13195-021-00813-8
78
TamagniniF.ScullionS.BrownJ. T.RandallA. D. (2015). Intrinsic excitability changes induced by acute treatment of hippocampal CA1 pyramidal neurons with exogenous amyloid β peptide. Hippocampus25 (7), 786–797. 10.1002/hipo.22403
79
TondoG.BoccaliniC.VanoliE. G.PresottoL.MuscioC.CiulloV.et al (2022). Brain metabolism and amyloid load in individuals with subjective cognitive decline or pre-mild cognitive impairment. Neurology99 (3), e258–e269. 10.1212/WNL.0000000000200351
80
TracyT. E.Madero-PérezJ.SwaneyD. L.ChangT. S.MoritzM.KonradC.et al (2022). Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration. Cell185 (4), 712–728.e14. 10.1016/j.cell.2021.12.041
81
van DyckC. H.SwansonC. J.AisenP.BatemanR. J.ChenC.GeeM.et al (2023). Lecanemab in early Alzheimer’s disease. N. Engl. J. Med.388, 9–21.
82
VargheseK.MolnarP.DasM.BhargavaN.LambertS.KindyM. S.et al (2010). A new target for amyloid beta toxicity validated by standard and high-throughput electrophysiology. PLoS One5 (1), e8643. 10.1371/journal.pone.0008643
83
WangY.ZhangG.ZhouH.BarakatA.QuerfurthH. (2009). Opposite effects of low and high doses of Aβ42 on electrical network and neuronal excitability in the rat prefrontal cortex. PLoS One4 (12), e8366. 10.1371/journal.pone.0008366
84
WangY.ZhouT. H.ZhiZ.BarakatA.HlatkyL.QuerfurthH. (2013). Multiple effects of β-amyloid on single excitatory synaptic connections in the PFC. Front. Cell. Neurosci.7 (SEP), 129. 10.3389/fncel.2013.00129
85
WangY.BalajiV.KaniyappanS.KrügerL.IrsenS.TepperK.et al (2017). The release and trans-synaptic transmission of Tau via exosomes. Mol. Neurodegener.12 (1), 5. 10.1186/s13024-016-0143-y
86
WeatheredC.BardehleS.YoonC.KumarN.LeynsC. E. G.KennedyM. E.et al (2024). Microglial roles in Alzheimer’s disease: an agent-based model to elucidate microglial spatiotemporal response to beta-amyloid. CPT Pharmacometrics Syst. Pharmacol.13 (3), 449–463. 10.1002/psp4.13095
87
WuJ. W.HussainiS. A.BastilleI. M.RodriguezG. A.MrejeruA.RilettK.et al (2016). Neuronal activity enhances tau propagation and tau pathology in vivo. Nat. Neurosci.19 (8), 1085–1092. 10.1038/nn.4328
88
YamadaK.HolthJ. K.LiaoF.StewartF. R.MahanT. E.JiangH.et al (2014). Neuronal activity regulates extracellular tau in vivo. J. Exp. Med.211 (3), 387–393. 10.1084/jem.20131685
Summary
Keywords
amyloid biomarkers, amyloid load negativity, functional outcome, plasma tau biomarkers, responder profiles
Citation
Geerts H, Short SM, Grant A and van der Graaf PH (2026) Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome. Insights from a comprehensive mechanistic quantitative systems pharmacology study. Front. Pharmacol. 17:1813290. doi: 10.3389/fphar.2026.1813290
Received
18 February 2026
Revised
30 March 2026
Accepted
03 April 2026
Published
30 April 2026
Volume
17 - 2026
Edited by
Marcelo Febo, University of Florida, United States
Reviewed by
Praveen Nekkar Rao, University of Waterloo, Canada
Seyedadel Moravveji, Montreal University, Canada
Updates
Copyright
© 2026 Geerts, Short, Grant and van der Graaf.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hugo Geerts, hugo.geerts@certara.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.